Arcus Biosciences (RCUS) Receivables - Other (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Receivables - Other of $4.0 million for Q1 2026, down 73.33% year-over-year from $15.0 million in Q1 2025, and down 63.64% quarter-over-quarter from $11.0 million in Q4 2025.
Arcus Biosciences (RCUS) Receivables - Other (2017 - 2026) Analysis & Trends
Arcus Biosciences' Receivables - Other history runs 10 years deep, the most recent figure standing at $4.0 million for Q1 2026.
- In Q1 2026, Receivables - Other fell 73.33% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (down 73.33% YoY), while the FY2025 annual figure was $11.0 million, down 45.0% from the prior year.
- Receivables - Other for Q1 2026 stood at $4.0 million, down from $11.0 million in the prior quarter.
- The five-year high for Receivables - Other was $52.0 million in Q3 2023, with the low at $4.0 million in Q1 2026.
- The 5-year median for Receivables - Other is $28.0 million (2024), against an average of $25.9 million.
- Peak annual rise in Receivables - Other reached 2944.89% in 2022, while the deepest fall reached 94.77% in 2022.
- Arcus Biosciences' Receivables - Other stood at $39.0 million in 2022, then dropped by 2.56% to $38.0 million in 2023, then slumped by 47.37% to $20.0 million in 2024, then slumped by 45.0% to $11.0 million in 2025, then plunged by 63.64% to $4.0 million in 2026.
- Business Quant data shows RCUS's Receivables - Other at $4.0 million in Q1 2026, $11.0 million in Q4 2025, and $11.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.00 Mn |
| Jun 30, 2026 | 36.00 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Dec 31, 2025 | 11.00 Mn |
| Dec 31, 2025 | 11.00 Mn |
| Sep 30, 2025 | 11.00 Mn |
| Sep 30, 2025 | 11.00 Mn |
| Jun 30, 2025 | 15.00 Mn |
| Jun 30, 2025 | 15.00 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 20.00 Mn |
| Dec 31, 2024 | 20.00 Mn |
| Sep 30, 2024 | 16.00 Mn |
| Sep 30, 2024 | 16.00 Mn |
| Jun 30, 2024 | 28.00 Mn |
| Jun 30, 2024 | 28.00 Mn |
| Mar 31, 2024 | 35.00 Mn |
| Mar 31, 2024 | 35.00 Mn |